Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Pharmascience Jurnal Psikiatri Surabaya (Surabaya Psychiatry Journal)
Dewi, Wahyu Ratna
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Effect of LAI Antipsychotics on Relapse Frequency and Adverse Drug Events of Schizophrenia Patients Sabar Parluhutan Siregar; Giyanto; Surya Sevriana, Ery; Pangestuti, Rayi Citra Ayu; Dewi, Wahyu Ratna
Jurnal Psikiatri Surabaya Vol. 14 No. 1 (2025): May
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jps.v14i1.62938

Abstract

Introduction: Non-adherence to oral antipsychotic medication is common in schizophrenia patients, and it is very likely to lead to recurrence. Whereas the frequency of recurrence in schizophrenia is associated with poorer long-term outcomes and disease progression. The use of long-acting injectable (LAI) antipsychotics has become a favorable approach in the management of schizophrenia, especially to reduce relapse rates and minimize treatment-related side effects. The aim of this study was to evaluate the effect of using LAI antipsychotics, specifically fluphenazine decanoate, on the relapse rate of schizophrenia patients as well as to assess the potential associated side effects. Methods: This study was a quantitative analytical study design with a retrospective cohort approach involving 1102 schizophrenia patients in RSJ Prof. Dr. Soerojo Magelang who received LAI therapy (fluphenazine decanoate) in various administration frequencies and time intervals. Data on relapse frequency and adverse drug events were obtained from medical records and adverse drug events yellow forms. The bivariate test used was a Wilcoxon signed rank test. Results: The results showed that 77.86% of respondents received LAI with an administration interval ≥ 180 days, and 92% received LAI with low administration frequency (1–5 times). There was a significant decrease between the frequency of relapse in schizophrenia patients and the incidence of drug side effects before and after the administration of antipsychotic LAI. Conclusions: In this study, it was found that the use of antipsychotic LAI (fluphenazine decanoate) can significantly reduce the frequency of relapse and the incidence of adverse drug events in schizophrenia patients.
Effectiveness of Clozapine and Its Potential Drug-Drug Interactions in Patients with Schizophrenia: A Study in Referral Psychiatric Hospital Puspita, Salma Fajar; Salsabila, Rifa; Dewi, Wahyu Ratna; Dwi Ananda Ningrum, Vitarani
Jurnal Pharmascience Vol 12, No 2 (2025): Jurnal Pharmascience
Publisher : Program Studi Farmasi FMIPA Universitas Lambung Mangkurat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20527/jps.v12i2.23111

Abstract

ABSTRAK Penelitian terkait efektivitas klozapin pada populasi Asia, baik sebagai monoterapi atau kombinasi, masih sangat terbatas. Selain itu, potensi interaksi antar-obat sering dijumpai pada pasien skizofrenia. Penelitian ini bertujuan untuk menganalisis respon terapeutik klozapin dan faktor-faktor yang memengaruhinya, serta interaksi obat-obat yang bersifat potensial. Penelitian cross-sectional retrospektif ini menggunakan data sekunder dari rekam medik pasien di rumah sakit jiwa rujukan di Jawa Tengah, Indonesia. Analisis data menggunakan uji Chi-square atau Fisher’s exact dengan SPSS versi 23. Studi melibatkan 149 pasien skizofrenia dengan mayoritas laki-laki dan terdiagnosis undifferentiated schizophrenia. Sebanyak 89,93% pasien mengalami perbaikan gejala klinis, sesuai yang dinyatakan dokter pada rekam medik, baik pada penggunaan klozapin tunggal maupun kombinasi terutama dengan risperidon. Respon terapeutik klozapin dipengaruhi secara signifikan hanya oleh usia (p<0,05). Sementara itu, interaksi obat potensial dengan klozapin berkategori mayor ditemukan pada 8,1% pasien. Penggunaan bersama risperidon diidentifikasi sebagai interaksi obat mayor terbanyak (79,25%) yang berisiko menimbulkan permasalahan kardiovaskular atau pernapasan. Penelitian ini merekomendasikan studi prospektif dengan penilaian efektivitas klozapin menggunakan PANSS-ES maupun dampak klinis interaksi obatnya. Kata Kunci: Klozapin, Skzofrenia, Efektivitas, Faktor Yang Memengaruhi, Interaksi Obat-Obat  Studies on clozapine effectiveness among Asian populations, either as monotherapy or in combination, are quite limited. In addition, potential drug-drug interactions (DDI) are common in schizophrenic patients. This study aimed to analyze the therapeutic response to clozapine, its influencing factors, and the potential DDI.  A cross-sectional study design retrospectively collected secondary data from medication records at the referral psychiatric hospitals in Central Java, Indonesia. Data analysis was performed using the Chi-square test or Fisher's exact test in SPSS version 23.   This study included 149 patients, predominantly male, who were diagnosed with undifferentiated schizophrenia. As many as 89.93% of patients experienced symptom improvement, as stated by the physician in the medical record, either as monotherapy or in combination, especially with risperidone. The therapeutic response to clozapine was significantly influenced only by age (p<0.05). Meanwhile, potential major drug interactions were found in 8.1% of patients. The combined use of clozapine with risperidone has been identified as having the most significant risk for drug interactions (79.25%), which can lead to cardiovascular or respiratory problems. This study recommends conducting prospective studies on the effectiveness of clozapine using the PANSS-ES scale and examine the clinical impact of the drug interactions.
Co-Authors Dwi Ananda Ningrum, Vitarani Giyanto Pangestuti, Rayi Citra Ayu Puspita, Salma Fajar Sabar Parluhutan Siregar Salsabila, Rifa Surya Sevriana, Ery